Tumor-associated macrophages (TAM) form a major component of the tumor stroma. However, important concepts such as TAM heterogeneity and the nature of the monocytic TAM precursors remain speculative. Here, we show for the first time that mouse mammary tumors contained functionally distinct subsets of TAMs and provide markers for their identification. Furthermore, in search of the TAM progenitors, we show that the tumor-monocyte pool almost exclusively consisted of Ly6C hi CX 3 CR1 low monocytes, which continuously seeded tumors and renewed all nonproliferating TAM subsets. Interestingly, gene and protein profiling indicated that distinct TAM populations differed at the molecular level and could be classified based on the classic (M1) versus alternative (M2) macrophage activation paradigm. Importantly, the more M2-like TAMs were enriched in hypoxic tumor areas, had a superior proangiogenic activity in vivo, and increased in numbers as tumors progressed. Finally, it was shown that the TAM subsets were poor antigen presenters, but could suppress T-cell activation, albeit by using different suppressive mechanisms. Together, our data help to unravel the complexities of the tumor-infiltrating myeloid cell compartment and provide a rationale for targeting specialized TAM subsets, thereby optimally "re-educating" the TAM compartment. Cancer Res; 70(14); 5728-39. ©2010 AACR.
Introduction
Myeloid cells are frequently found to infiltrate tumors and have been linked to diverse tumor-promoting activities (1) . In particular, tumor-associated macrophages (TAM) are an important component of the tumor stroma, both in murine models and human patients (2) . TAMs can promote tumor growth by affecting angiogenesis, immune suppression, and invasion and metastasis (2, 3) . However, it seems unlikely that these diverse functions are performed by a single cell type, and the existence of distinct TAM subsets, linked to different intratumoral microenvironments, has been predicted (4) . Nevertheless, studies identifying spatially and functionally distinct TAM subpopulations are currently lacking.
Tissue-resident macrophages can be maintained through local proliferation or differentiation in situ from circulating monocytic precursors (5) . Importantly, discrete subsets of blood monocytes have been described. Mouse monocytes can be classified as Ly6C low CX 3 CR1 hi (CCR2 − CD62L − ) or Ly6C hi CX 3 CR1 low (CCR2 + CD62L + ) and are shown to have distinct functions and migration patterns (6) . However, information on the nature and dynamics of the monocytic TAM precursors is lacking thus far.
Macrophages are plastic cells that can adopt different phenotypes depending on the immune context. Microenvironmental stimuli can drive a macrophage either toward a "classic" (M1) or an "alternative" (M2) activation state, two extremes in a spectrum (7) . M1 macrophages are typically characterized by the expression of proinflammatory cytokines, inducible nitric oxide synthase 2 (Nos2), and MHC class II molecules. M2 macrophages have a decreased level of the aforementioned molecules and are identified by their signature expression of a variety of markers, including arginase-1 and mannose and scavenger receptors. It has been suggested that TAMs display an M2-like phenotype (8) , although it is not clear whether these findings can be generalized and are applicable to TAMs in different tumor regions. In addition, the processes and signaling pathways that are driving the M2 phenotype of TAMs are not yet fully understood. A factor that is believed to be crucial in shaping the TAM phenotype is tumor hypoxia (9) . Although hypoxia is known to have dramatic effects on the activation and function of macrophages, it remains to be determined how this relates to the M2-like orientation of TAMs.
In this study, we show the existence of molecularly and functionally distinct TAM subsets, located in different intratumoral regions, and uncover Ly6C hi monocytes as their precursors. These results might prove important for therapeutic interventions targeted at specific TAM subsets or their precursors.
Materials and Methods

Mice, cell lines
Female BALB/c and C57BL/6 mice were from Harlan. BALB/c CX 3 CR1
GFP/GFP mice were provided by Dr. Grégoire Lauvau (Université de Nice-Sophia Antipolis, Nice, France). The BALB/c mammary adenocarcinoma TS/A (10) was provided by Dr. Vincenzo Bronte (Istituto Oncologico Veneto, Padova, Italy); BALB/c 4T1 mammary carcinoma (11) was provided by Dr. Massimiliano Mazzone (VIB-KULeuven, Leuven, Belgium); and 3LL-R clone of the C57BL/6 Lewis Lung carcinoma was derived as described previously (12) . Cells were injected subcutaneously (s.c.) in the flank (3 × 10 6 ) or in the mammary fat pad (10 6 ).
Tumor preparation, fluorescence-activated cell sorting Tumors were treated with 10 U/mL collagenase I, 400 U/mL collagenase IV, and 30 U/mL DNaseI (Worthington). Density gradients (Axis-Shield) were used to remove debris and dead cells. To purify TAMs, CD11b + cells were MACS-enriched (anti-CD11b microbeads, Miltenyi Biotec) and sorted using a BD FACSAria II (BD Biosciences). To purify dendritic cells, spleens were flushed with 200 U/mL collagenase III (Worthington). CD11c + cells were MACS-enriched (anti-CD11c microbeads, Miltenyi Biotec), and CD11c
Ly6C
− dendritic cells were sorted.
Antibodies used are listed in Supplementary Table S1 . For tumor necrosis factor α (TNFα) stainings, TAMs were cultured 5 hours with Brefeldin A (BD Biosciences). For inducible nitric oxide synthase (iNOS), TAMs were cultured with 10 U/mL IFNγ and/or 10 ng/mL lipopolysaccharide (LPS) for 12 hours.
Arginase activity was measured as described earlier (13) .
In vivo monocyte labeling Latex labeling of monocytes was described earlier (14, 15) . For Ly6C low monocyte labeling, mice were injected intravenously (i.v.) with 250 μL 0.5 μm yellow-green microspheres (Polysciences; 1:25). Twenty-four hours later, TS/A was injected s.c. For Ly6C hi monocyte labeling, mice were injected i.v. with 250 μL clodronate liposomes (16) and 18 hours later with latex microspheres (i.v.) and TS/A (s.c.).
Bromodeoxyuridine staining, cell cycle analysis
Mice were injected intraperitoneally with 1 mg bromodeoxyuridine (BrdUrd) (Sigma), and 0.8 mg/mL BrdUrd was administered to drinking water. To stain for BrdUrd, Ki67 (BD Biosciences), or propidium iodide (Invitrogen), cells were fixed/permeabilized using the BD Biosciences BrdUrd labeling kit.
RNA extraction, cDNA preparation, and quantitative reverse transcriptase-PCR
These tests were performed as described earlier (17) . Gene-specific primers are listed in Supplementary Table S2 .
Immunohistochemistry, hypoxia measurements
For hypoxia stainings, mice were injected with 80 mg/kg body weight pimonidazole [hypoxyprobe-1 (HP-1), HPI, Inc.]. Two hours later, tumors were snap frozen, sections were acetone fixed, and stained. Pictures were acquired with a Plan-Neofluar 10×/0.30 or Plan-Neofluar 20×/0.50 (Carl Zeiss) objective on a Zeiss Axioplan 2 microscope equipped with an Orca-R2 camera (Hamamatsu) and Smartcapture 3 software (Digital Scientific UK). For HP-1 fluorescence-activated cell sorting (FACS) measurements, cells were fixed/permeabilized using the BD Biosciences Fix/Perm kit and rat anti-HP-1/ FITC (HPI) was added (30-37°C).
Chorioallantoic membrane assays
Chorioallantoic membrane (CAM) assays were performed as described earlier (18) . Gelatin sponges (1-2 mm 3 ; Hospithera) with 5 × 10 4 sorted TAM subsets were placed on the CAM. PBS/ 0.1% bovine serum albumin (BSA; 50 μg/CAM) and recombinant human vascular endothelial growth factor (VEGF)-A 165 (5 μg/CAM) served as controls. At day 13, membranes were fixed and analyzed using a Zeiss Lumar V.12 stereomicroscope with NeoLumar S 1.5× objective (15× magnification).
Mixed leukocyte reaction, suppression assays
For allo-mixed leukocyte reaction (MLR) assays, 3 H]thymidine pulsed 24 hours later. L-NMMA (0.5 mmol/L, Sigma) and/or NorNoha (0.5 mmol/L, Calbiochem) were added in a 1:4 ratio. Relative percent suppression of proliferation was calculated as described earlier (19) .
Statistics
Significance was determined by Student's t test.
Results
TS/A tumors are highly infiltrated with a heterogeneous population of myeloid cells containing distinct granulocyte and monocyte/macrophage subsets To study the tumor-infiltrating myeloid compartment, we, at first instance, used the BALB/c mammary adenocarcinoma model TS/A. Subcutaneous tumors contained a large CD11b + fraction, indicating a high infiltration of myeloid cells (Fig. 1A) . Interestingly, this CD11b + population was heterogeneous and encompassed at least seven subsets, which could be readily distinguished based on their differential expression of MHC class II and Ly6C (Fig. 1A) GFP/+ mice. Shaded histograms, isotype control (n = 6).
the granulocyte markers Ly6G or CCR3, and had a small size and granularity (FSC low SSC low ), indicating that they were Ly6-C hi monocytes ( Fig. 1A and D; Supplementary Fig. S1 ). The CD11b + MHC II + cells in gates 2 to 4 were reminiscent of macrophages, having an enlarged macrophage-like scatter and expressing high levels of F4/80 (Fig. 1A and D Supplementary Fig. S1 , gate 2) and CCR3 − CX 3 CR1 hi ( Supplementary Fig. S1 , gate 3) cells, the latter possibly resembling Ly6C low CX 3 CR1 hi monocytes. However, the majority of these CX 3 CR1
hi cells did not have a monocyte scatter, suggesting they were TAMs (Supplementary Fig. S1 ). This suggests that Ly6C low monocytes were not present in significant amounts in these tumors. Finally, TS/A tumors were also infiltrated with CCR3 + Ly6C int eosinophils (Fig. 1A , gate 6) and Ly6G hi neutrophils (Fig. 1A , gate 7). Interestingly, the relative percentages of these distinct myeloid subpopulations dramatically changed as tumors progressed (Fig. 1B) . Within the TAM compartment, the percentage of Ly6C int TAMs decreased, whereas the Ly6-C low MHC II low TAM subset became gradually more prominent, reaching up to 60% of the myeloid tumor infiltrate in large tumors (>10 mm). Because the amount of tumor-infiltrating CD11b + cells increased as tumors progressed (Fig. 1C ), MHC II low TAMs also strongly accumulated in absolute numbers, to a much greater extent than MHC II hi TAMs.
Ly6C hi monocytes are the precursors of all TAM subsets in TS/A tumors
Macrophages typically derive from circulating blood-borne precursors such as monocytes. The presence of Ly6C hi , but not Ly6C low , monocytes in TS/A tumors suggested that the former could be more efficiently recruited to tumors and function as the TAM precursor. To investigate this, we selectively labeled Ly6C hi or Ly6C low monocyte subsets in vivo with fluorescent latex beads, using a previously described procedure (14, 15) . This method has been validated to stably label the respective monocyte subsets for 5 to 6 days in naive mice. Hence, TS/A was injected after Ly6C low or Ly6C hi monocyte labeling, and tumors were collected 6 days post injection. No appreciable numbers of tumor-infiltrating latex + monocytes were observed when applying the Ly6C lowlabeling strategy ( Fig. 2A) hi monocytes. Remarkably, the total number of peripheral blood monocytes had significantly increased at later stages of tumor growth (≥21 days post injection; Supplementary Fig. S2A ). Furthermore, around 4 weeks of tumor growth, there was a significant increase in the percentage of the Ly6C hi monocyte subset ( Supplementary Fig. S2B-C To determine the turnover rate and differentiation kinetics of the monocyte/TAM subsets, BrdUrd was administered continuously to tumor-bearing animals and its incorporation was measured at consecutive time points. Tumor-infiltrating Ly6C hi monocytes quickly became BrdUrd + , reaching plateau values after 48 hours of BrdUrd administration (Fig. 2C ). This indicates a rapid monocyte turnover rate and/or proliferation of monocytes inside tumors. Remarkably, although intratumoral Ly6C hi monocytes were Ki67 + ( Fig. 2D1 ), none were found to be in the S-G 2 -M phase ( Fig. 2D2) , suggesting that these cells were in the G 1 phase and not proliferating (20 (Table 1 , hi/low), M2-associated genes such as Arg1 (arginase-1), Cd163, Stab1 (stabilin-1), and Mrc1 (MMR) were higher expressed in the MHC II low subset. In contrast, more M1-type, proinflammatory genes, such as Nos2 (iNOS), Ptgs2 (Cox2), Il1b, Il6, and Il12b, were upregulated in MHC II hi TAMs. This differential activation state was also reflected at the protein level. Membrane expression of the M2 markers macrophage mannose receptor (MMR), macrophage scavenger receptor 1 (SR-A), and interleukin-4Rα (IL-4Rα) were clearly higher on MHC II low TAMs, whereas the M1-associated marker CD11c was only expressed on MHC II hi TAMs (Fig. 1D) . Moreover, although arginase activity was observed in both TAM subsets, it was significantly higher for MHC II low TAMs (Fig. 3A) . In the same vein, TNFα, which has previously been reported to associate with a M2 phenotype in tumors (23, 24) , was produced by both TAM subsets; however, a significantly higher percentage of MHC II low TAMs were found to be TNFα + (Fig. 3B ). Although iNOS protein was not detected in freshly isolated TAMs, it could be induced by IFN-γ and/or LPS stimulation (Fig. 3C) TAM subsets also showed a markedly distinct chemokine expression pattern (Table 1) . Notably, mRNAs for chemokines typically involved in lymphocyte attraction, such as Ccl5, Cx 3 cl1, Cxcl11, Cxcl10, Cxcl9, and the CCR4 ligands Ccl17 and Ccl22 were upregulated in MHC II hi TAMs. In contrast, mRNAs for monocyte/macrophage chemoattractants, such as Ccl6; the CCR2 ligands Ccl7, Ccl2, and Ccl12; and the CCR5/CCR1 ligands Ccl4, Ccl3, and Ccl9 were significantly higher in MHC II low TAMs. Furthermore, at the protein level, a differential expression of the chemokine receptors CX 3 CR1 and CCR2 was observed, with MHC II hi TAMs being C X 3 C R 1 h i C C R 2 − , w h e r e a s M H C I I l o w T A M s w e r e CX 3 CR1 low CCR2 + (Fig. 1D ). Both TAM subsets expressed many potentially proangiogenic genes, including Vegfa, Mmp9, Pgf, Spp1, and cathD (Table 1) . However, several angiostatic factors such as angpt2, Cxcl9, Cxcl10, and Cxcl11 were upregulated in the MHC II hi fraction. One of the most differentially expressed genes (higher in MHC II low TAMs) was Lyve1, a marker previously associated with angiogenic/hypoxic macrophages (25) .
We tumors contained identical myeloid subsets, which accumulated with comparable kinetics (Supplementary Fig. S4A ) and retained their differential expression of surface markers ( Supplementary Fig. S4B ). We then investigated whether differentially activated TAM subsets were present in other tumor models. Interestingly, orthotopic 4T1 mammary and subcutaneous 3LL lung carcinoma tumors contained distinct granulocyte and monocyte/ macrophage subsets ( Supplementary Figs. S5A and S6A MHC II low TAMs are enriched in regions of hypoxia, whereas MHC II hi TAMs are mainly normoxic Tumors often harbor regions of hypoxia, a factor that is known to influence macrophage function (9) . To visualize hypoxia in TS/A tumors, tumor-bearing mice were injected with pimonidazole (HP-1) and tumor sections were stained for hypoxic adducts and blood vessels. Figure 4A shows This indicates that whereas a significant fraction of MHC II low TAMs resided in hypoxic areas, MHC II hi TAMs were mainly normoxic. Importantly, HP-1 adducts could also be detected through intracellular flow cytometry on freshly isolated TAMs. Again, the highest signal was seen in MHC II low TAMs, confirming they were the most hypoxic TAM subset (Fig. 4C) . A consequence of MHC II low TAMs being in hypoxic regions should be a reduced access to blood-transported molecules. To test this, fluorescent latex particles were injected i.v. in tumorbearing mice. One to 2 hours later, a fraction of tumor-associated CD11b + cells were found to be latex + ( Supplementary Fig. S8A ). However, latex uptake was not equal in all TAM subsets. Indeed, in relative terms, MHC II low TAMs phagocytosed less latex than monocytes and other TAM subsets. This was not due to an inherently reduced phagocytic capacity of MHC II low TAMs because the latter showed the highest phagocytic latex uptake in vitro (Supplementary Fig. S8B ). These data suggest that the reduced in vivo latex uptake of MHC II low TAMs was due to a restricted access to latex particles, which further substantiates the enrichment of MHC II low TAMs in hypoxic regions. 
MHC II low TAMs show a superior proangiogenic activity in vivo
Hypoxia initiates an angiogenic program (26) . In addition, our gene profiling revealed the expression of angiogenesisregulating molecules in TAMs. To directly test the proangiogenic activity of both TAM subsets in vivo, we used the CAM assay. Sorted MHC II hi or MHC II low TAMs were implanted on developing CAMs, whereas BSA or rhVEGF served as negative and positive controls, respectively. rhVEGF induced the outgrowth of allantoic vessels specifically directed toward the implants (Fig. 5A) . Interestingly, compared with BSA controls, the presence of MHC II hi or MHC II low TAMs significantly increased the number of implant-directed vessels, demonstrating a proangiogenic activity for both TAM subsets. However, the vessel count for implants containing MHC II low TAMs was on average 2-fold higher than with MHC II hi TAMs. These data show that MHC II low TAMs had a superior proangiogenic activity in vivo.
TAMs are poor antigen presenters, but can efficiently suppress T-cell proliferation
We wondered whether the TAM subsets were able to process internalized antigens and activate T cells. Both TAM subsets took up and processed DQ-Ovalbumin at 37°C. However, examining DQ-Ovalbumin processing at consecutive time points indicated that processing occurred more slowly in the MHC II low fraction (Supplementary Fig. S9 ). To investigate whether TAMs could directly activate naive T cells, a MLR assay was used. Sorted MHC II hi or MHC II low TAMs were cultured with purified allogeneic C57BL/6 CD4 + or CD8 + T cells. Sorted splenic CD11c hi MHC II hi conventional dendritic cells (Supplementary Fig. S3D ) were used as a reference T-cell-stimulating population (27) . Compared with conventional dendritic cells, MHC II hi or MHC II low TAMs induced poor proliferation of allogeneic CD4 + or CD8 + T cells (Fig. 5B) , suggesting a limited antigen-presenting capacity or, alternatively, a T-cell suppressive capacity that overrules antigen presentation.
To investigate the latter possibility, T cells were polyclonally activated in the presence of TAMs or conventional dendritic cells. Interestingly, as opposed to conventional dendritic cells, both MHC II hi and MHC II low TAMs equally suppressed anti-CD3-induced T-cell proliferation in a dosedependent manner (Fig. 5C) . In an attempt to identify the suppressive molecules responsible for TAM-mediated suppression, inhibitors of iNOS (L-NMMA) and arginase (NorNoha) were added to the cocultures (Fig. 5D) . Blocking iNOS significantly reduced T-cell suppression by MHC II hi TAMs, demonstrating a role for nitric oxide in its suppressive mechanism. In contrast, iNOS inhibition only had a minor effect on the suppressive potential of MHC II low TAMs, showing that both subsets use different T-cell suppressive mechanisms.
Discussion
In this article, we show that the tumor-infiltrating myeloid compartment can be highly heterogeneous, with the coexistence of distinct subsets of granulocytes and mononuclear phagocytes. Furthermore, we identified the nature and dynamics of the monocyte precursor that was seeding tumors and giving rise to distinct TAM subsets. Interestingly, these subsets differed at the molecular and functional levels and were present in different intratumoral microenvironments (for an overview, see Supplementary Fig. S10 ).
Within the tumor-infiltrating monocyte pool, Ly6C hi CX 3-CR1 int monocytes were the most prominent subset, whereas Ly6C low CX 3 CR1 hi monocytes constituted only a small minority. In addition, bead labeling and BrdUrd incorporation experiments showed that Ly6C hi monocytes were the precursors of all the distinct TAM subsets in TS/A tumors. Ly6C hi monocytes rely on the chemokine receptor CCR2 for their migration from the bone marrow into the circulation (28 (35) . However, our results show that at the tumor site, Ly6C hi monocytes exclusively gave rise to distinct subsets of inflammatory macrophages, further highlighting monocyte plasticity and the impact of the tumor microenvironment thereon.
Strikingly, MHC II hi and MHC II low TS/A TAMs tended to be more M1-or M2-like, respectively. At the protein level, this included the differential expression of the M1 markers MHC II, CD11c, and iNOS, and the typical M2 markers MMR, SR-A, IL-4Rα, and arginase-1. Further proof for a differential activation state was delivered by gene expression analysis: an upregulation of proinflammatory genes in MHC II hi TAMs, whereas M2-associated genes preferentially adhered to the MHC II low subset. Interestingly, Hagemann and colleagues described that macrophages cocultured with ovarian cancer cells obtain an M2-like phenotype reminiscent of the MHC II low TAMs in our present study, including upregulation of MMR, SR-A, and high expression levels of TNFα (23) . In follow-up studies, it was shown that inhibiting IκB kinase (IKK) β activity in these macrophages results in a switch from M2 to M1, as evidenced by enhanced expression of MHC II, iNOS, and IL-12, and a reduction in arginase, TNFα, and IL-4Rα (24, 36) . Hence, MHC II hi TAMs more closely resemble the phenotype of the IKKβ-deficient macrophages, raising the possibility that the opposing activation states of MHC II hi and MHC II low TAMs might be driven by a differential NF-κB activity in these subsets.
Importantly, our findings in TS/A could be translated to 4T1 and 3LL tumors. The remarkable similarities between TAM subsets from these unrelated tumors suggest that similar environmental cues might shape their respective phenotypes.
Interestingly, in TS/A tumors, MHC II low TAMs were found to preferentially reside in hypoxic regions, as shown by pimonidazole stainings and their reduced access to bloodtransported molecules. Hypoxia is known to influence gene and protein expression of macrophages: inducing expression of arginase, TNF, and proangiogenic factors while downregulating MHC II (37) (38) (39) . Hypoxia-inducible factors (HIF) are the main transcription factors involved in regulating hypoxia-driven gene expression (26) . Interestingly, a recent report showed that IKKβ is required for HIF-1α accumulation under hypoxic conditions, thereby uncovering a link between the hypoxic response and NF-κB (40) . Hence, it is tempting to speculate that the involvement of IKKβ in shaping the M2 activation state of macrophages and its requirement for HIF-1α activity might be involved in the M2 skewing of hypoxic TAMs. Irrespective of the molecular mechanism, these are the first data linking the M2-like orientation of TAMs with a hypoxic environment.
Another (43) , it is tempting to speculate that the similarities between TEMs and MHC II low TAMs might reflect a comparable function. Indeed, one of the key responses to hypoxia is the induction of an angiogenic program (26) .
An in vivo CAM assay showed that both TS/A TAM subsets stimulated angiogenesis. Interestingly, however, in line with their localization in hypoxic regions, MHC II low TAMs showed a significantly higher proangiogenic activity, indicating that the balance of proangiogenic versus antiangiogenic mediators was highest for this subset. At present, the exact molecular basis for the increased angiogenic potential of MHC II low TAMs is not clear, as several proangiogenic genes were expressed at a high level in both TAM populations. However, MHC II hi TAMs had the highest expression of the antiangiogenic CXC chemokines (Cxcl9-11; ref. 44) , potentially limiting the effects of proangiogenic factors.
The induction of myeloid-derived suppressor cells (MDSC) is shown to be an important immune-evading strategy used by tumors (45, 46 TAMs were able to process antigens (albeit with different kinetics), they inefficiently activated naive T cells. In contrast, both subsets strongly suppressed polyclonal T-cell proliferation. Interestingly, in line with their M1-like activation, MHC II hi TAMs relied to a higher extent on iNOS for suppression.
It has been predicted that TAMs in different tumor regions might have specialized functions (4). Our results provide the first evidence for this and describe markers for their discrimination in three independent tumor models. This offers the prospect of specifically targeting the M1-/M2-like or hypoxic/ perivascular TAM subsets and investigating their impact on tumor biology. Eventually, this might lead to combinatorial strategies for optimally "re-educating" the TAM compartment and reverting its tumor-promoting activities.
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